Publications by authors named "Kyung Jin Yoo"
Article Synopsis
- Immunotherapy using PD-(L)1 blockade is common for treating non-small cell lung cancer (NSCLC), but over 60% of initial responders develop acquired resistance.
- Research indicates that this resistance is linked to differences in inflammation and interferon (IFN) signaling, with relapsed tumors showing varied expressions of IFNγ response genes.
- Understanding the altered IFN response in these tumors may help develop new strategies to overcome resistance and improve treatment effectiveness.
Article Synopsis
- Vγ9Vδ2 T cell immunotherapy is being explored for its ability to fight various cancers by leveraging its unique cytotoxic properties that don't rely on MHC recognition.
- Researchers have found that the BTN2A1 and BTN3A1 proteins provide the primary activation signal (signal 1) for Vγ9Vδ2 T cells, while the details surrounding the necessary secondary signal (signal 2) needed for full activation remain uncertain.
- In experiments, a BTN2A1/3A1 fusion protein activated Vγ9Vδ2 T cells when combined with costimulatory signals, and it also boosted the cancer-killing ability of these T cells against CD19 lymphoma cells, indicating that tumor cells
Article Synopsis
- Combining TIGIT and PD-1/PD-L1 blockade could enhance cancer treatment effectiveness in patients with high PD-L1 expression and no prior checkpoint therapy.
- TIGIT-Fc-LIGHT fusion proteins stimulate the immune response by activating myeloid cells and enhancing the function of CD8 T and NK cells, potentially overcoming resistance to existing PD-1 therapies.
- The research indicates that LIGHT, as an immune costimulator, may expand the therapeutic benefits of TIGIT blockade in a broader range of tumor types, addressing limitations in treatment for resistant cancers.
Article Synopsis
- Disrupting the interaction between CD47 and SIRPα is a promising approach in cancer immunotherapy, as it boosts the ability of antibodies to promote the phagocytosis (engulfing) of cancer cells by immune cells.
- A new fusion protein called SIRPα-Fc-CD40L has been developed, which effectively binds to CD47 and CD40, activating important immune signaling without harmful side effects in tests with monkeys.
- In experiments with tumor-bearing mice, SIRPα-Fc-CD40L demonstrated superior effects compared to traditional treatments, enhancing immune responses and promoting long-lasting tumor control and rejection.
Purpose: To investigate the influence of dentifrices with and without abrasives on the wear and surface topography of human dentin following simulated toothbrushing in vitro.
Methods: 24 dentin specimens were prepared and randomly allocated to a liquid dentifrice (Garglin Gum-Guard), conventional dentifrice (333 Clinic Total Care), and control (distilled water) groups. Specimens were subjected to simulated toothbrushing of 50,000 repeated strokes under a 150 g-load.